Alimera Sciences Announces Presentation Of Data From The 12-Month Interim Readout Of The Human PK ILUVIEN™ Study At ARVO 2009 Annual Meeting
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that positive interim 12-month safety and efficacy results from the... [more]
